Amid PD-1 Uncertainty, Bristol Under Pressure For M&A Activity
Bristol says its checkpoint immunotherapies can hold the lead in renal cell carcinoma, despite increasing competition.
You may also be interested in...
Q1 Earnings Preview: With the positive vote on its merger with Celgene behind it, Bristol now needs to focus on growing its immuno-oncology business, where several upcoming catalysts could bolster Opdivo.
Wellington, the largest institutional shareholder in Bristol, and activist firm Starboard both have publicly opposed the Bristol/Celgene merger but the strong crossover of investors in both biopharmas suggests the deal will still obtain approval.
Withdrawal of filing of CheckMate 227 data in patients with high tumor mutational burden (TMB) means another delay for Opdivo in first-line lung cancer.